Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort

References

• JacobsLCookfairDRudickRIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol1996392852948602746
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupRandomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosisLancet1998352149815049820297
   PubMed Web of Science ®Google Scholar
• FilippiniGMunariLIncorvaiaBInterferons in relapsing remitting multiple sclerosis: a systematic reviewLancet200336154555212598138
   PubMed Web of Science ®Google Scholar
• CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health200811444718237359
   PubMed Web of Science ®Google Scholar
• MenzinJCaonCNicholsCWhiteLAFriedmanMPillMNarrative review of the literature on adherence to disease-modifying therapies among patients with mutiple sclerosisJ Manag Care Pharm2013191-aS24S4023383731
   PubMed Web of Science ®Google Scholar
• World Health OrganizationAdherence to long-term therapies – evidence for action2003 Available from: http://www.who.int/chp/knowledge/publications/adherence_introduction.pdfAccessed September 1, 2009
   Google Scholar
• OsterbergLBlaschkeTAdherence to medicationNew Engl J Med200535348749716079372
   PubMed Web of Science ®Google Scholar
• SimpsonSEurichDMajumdarSA meta-analysis of the association between adherence to drug therapy and mortalityBMJ200633375571516790458
   PubMed Web of Science ®Google Scholar
• SokolMMcGuiganKVebruggeREpsteinRImpact of medication adherence on hospitalization risk and healthcare costsMed Care20054352153015908846
   PubMed Web of Science ®Google Scholar
• TanHCaiQAgarwalSStephensonJKamatSImpact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdv Ther201128516121153000
   PubMed Web of Science ®Google Scholar
• SteinbergSFarisRChangCChanATankersleyMImpact of adherence to interferons in the treatment of multiple sclerosis – a non-experimental, retrospective, cohort studyClin Drug Investig20103089100
   PubMed Web of Science ®Google Scholar
• IvanovaJBergmanRBirnbuamHPhillipsAStewartMMeleticheDImpact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the USJ Med Econ20121560160922376190
   PubMedGoogle Scholar
• HansenKSchusselKKiebleMAdherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort studyPLoS One2015107e013327926214805
   PubMed Web of Science ®Google Scholar
• EvansCMarrieRAZhuFAdherence and persistence to drug therapies for multiple sclerosis: a population-based studyMult Scler Relat Disord20168788527456879
   PubMed Web of Science ®Google Scholar
• MilaneseCLa MantiaLPalumboRA post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patientsJ Neurol Neurosurg Psychiatry2003741689169214638892
   PubMed Web of Science ®Google Scholar
• PortaccioEZipoliVSiracusaGSorbiSAmatoMLong-term adherence to interferon B therapy in relapsing-remitting multiple sclerosisEur Neurol20075913113518057899
   PubMed Web of Science ®Google Scholar
• LafataJCerghetMDobieEMeasuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosisJ Am Pharm Assoc200848752757
   Google Scholar
• DaughertyKButlerJMattinglyMRyanMFactors leading patients to discontinue multiple sclerosis therapiesJ Am Pharm Assoc200545371375
   Google Scholar
• O’RourkeKHutchinsonMStopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patternsMult Scler200511465015732266
   PubMed Web of Science ®Google Scholar
• KlauerTZettlUCompliance, adherence, and the treatment of multiple sclerosisJ Neurol2008255Suppl 6879219300966
   PubMed Web of Science ®Google Scholar
• TremlettHOgerJInterrupted therapy – stopping and switching of the B-interferons prescribed for MSNeurology20036155155412939437
   PubMed Web of Science ®Google Scholar
• ClericoMBarberoPContessaGFerreroCDurelliLAdherence to interferon-beta treatment and results of therapy switchingJ Neurol Sci200725910410817376486
   PubMed Web of Science ®Google Scholar
• Health Information Managment BranchPopulation ReportWinnipeg, MBManitoba Health and Healthy Living2008
   Google Scholar
• MarrieRYuNBlanchardJLeungSElliotLThe rising prevalence and changing age distribution of multiple sclerosis in ManitobaNeurology20107446547120071664
   PubMed Web of Science ®Google Scholar
• EvansCTamJKingwellEOgerJThe UBC Neurologists, Tremlett HLong-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database studyClin Ther20123434135022296946
   PubMed Web of Science ®Google Scholar
• ReynoldsMStephenRSeamanCRajagopalanKPersistence and adherence to disease modifying drugs among patients with multiple sclerosisCurr Med Res Opin20102666367420070144
   PubMed Web of Science ®Google Scholar
• KarveSClevesMHelmMHudsonTWestDMartinBGood and poor adherence: optimal cut-point for adherence measures using administrative claims dataCurr Med Res Opin2009252303231019635045
   PubMed Web of Science ®Google Scholar
• SidakZRectangular confidence regions for the means of multivariate normal distributionsJ Am Statist Assoc196762626633
   Web of Science ®Google Scholar
• ZhornitskySGreenfieldJKochMLong-term persistence with injectable therapy in relasping–remitting multiple sclerosis: an 18-year observational cohort studyPLoS One2015104e012382425867095
   PubMed Web of Science ®Google Scholar
• MocciaMPalladinoRCarotenutoAPredictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosisMult Scler Relat Disord201610909627919507
   PubMed Web of Science ®Google Scholar
• NguyenT-M-ULa CazeACottrellNWhat are validated self-report adherence scales really measuring?: a systematic reviewBr J Clin Pharmacol201377427445
   Web of Science ®Google Scholar
• CramerJRoyABurrellAFairchildCFuldeoreMOllendorfDMedication compliance and persistence: terminology and definitionsValue Health200811444718237359
   PubMed Web of Science ®Google Scholar
• YeawJBennerJWaltJSianSSmithDComparing adherence and persistence across 6 chronic medication classesJ Manag Care Pharm20091572874019954264
   PubMed Web of Science ®Google Scholar
• CorreiaIMarquesIBSousaMPredictors of first-line treatment persistence in a Portuguese cohort of relapsing–remitting multiple sclerosisJ Clin Neurosci201633737827542939
   PubMed Web of Science ®Google Scholar
• La MantiaLDi PietrantonjCRovarisMInterferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosisCochrane Database Syst Rev201611CD00933327880972
   PubMed Web of Science ®Google Scholar
• McHorneyCSpainCFrequency of and reasons for medication non-fulfillment and non-persistence among American adults with chronic disease in 2008Health Expect20101430732020860775
   PubMed Web of Science ®Google Scholar
• BrownMBussellJMedication adherence: WHO cares?Mayo Clin Proc20118630431421389250
   PubMed Web of Science ®Google Scholar
• TreadawayKCutlerGSalterALynchSSimsarianJCorboyJFactors that influence adherence with disease-modifying therapy in MSJ Neurol200925656857619444532
   PubMed Web of Science ®Google Scholar
• DevonshireVLapierreYMacdonellRThe Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relasping–remitting multiple sclerosisEur J Neurol201118697720561039
   PubMed Web of Science ®Google Scholar
• FoxRSalterATyryTTreatment discontinuation and disease progression with injectable disease-modifying therapies – Findings from the North American Research Committee on Multiple Sclerosis DatabaseInt J MS Care20131519420124453783
   PubMedGoogle Scholar
• DiMatteoMRHaskardKWilliamsSHealth beliefs, disease severity, and patient adherence: a meta-analysisMed Care20074552152817515779
   PubMed Web of Science ®Google Scholar
• MarrieRAElliotLMarriottJDramatically changing rates and reasons for hospitalization in multiple sclerosisNeurology20148392993725085638
   PubMed Web of Science ®Google Scholar
• ButlerMForteMSchwehrNCarpenterAKaneRDecisional Dilemmas in Discontinuing Prolonged Disease-Modifying Treatment for Multiple SclerosisMinnesota Evidence-based Practice Centre: Agency for Healthcare Research and Quality2015
   Google Scholar
• FreedmanMSelchenDArnoldDTreatment optimization in MS: Canadian MS Working Group Updated RecommendationsCan J Neurol Sci20134030732323603165
   PubMed Web of Science ®Google Scholar
• KisterISpelmanTDuquettePDoctor, can I stop my medicine? Analysis of disease course after stopping disease-modifying therapy in stable MS patients (P5.192)Neurology201584Supplement 5192
   Google Scholar
• BonenfantJBajeuxEDeburghgraeveVLe PageEEdanGKerbratACan we stop immunomodulatory treatments in secondary progressive multiple sclerosis?Eur J Neurol20172423724427753181
   PubMed Web of Science ®Google Scholar
• QuailJLixLOsmanBATeareGComparing comorbidity measures for predicting mortality and hospitalization in three population-based cohortsBMC Health Serv Res20111114621663672
   PubMed Web of Science ®Google Scholar